11 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
by the FDA when there is reasonable evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of all
ARS
2023 FY
CCCC
C4 Therapeutics Inc
28 Apr 23
Annual report to shareholders
7:03am
in the labeling of prescription drugs or drug products by the FDA when there is reasonable evidence of an association of a serious hazard with the drug
10-K
2020 FY
CCCC
C4 Therapeutics Inc
11 Mar 21
Annual report
4:19pm
evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of all labeling claims sought by an applicant
424B4
hyb25 axw
2 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
liafz0q bq8l
28 Sep 20
IPO registration (amended)
6:07am
S-1
a52g 12st
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.14
dtctsa6prxk739 ql
10 Sep 20
IPO registration
5:26pm
DRS
EX-10.9
h7zry4b7bj6m
6 Aug 20
Draft registration statement
12:00am
DRS
11wltgnrxtil5n
6 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next